Innovations in the Management of Dyspareunia

Innovations in the Management of Dyspareunia

Innovations in the Management of Dyspareunia
Dr. Allen is joined by Dr. Portman to discuss the diagnosis of dyspareunia and the therapies indicated for the management of this condition.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Vulvar vaginal atrophy (VVA) affects about half of the 64 million postmenopausal women in the U.S. VVA is the loss of estrogen stimulation on vaginal and vulvar tissue, resulting in atrophy of these tissues and these women may suffer from symptoms, which include dyspareunia - or painful sexual intercourse. With this, dyspareunia can negatively impact a woman’s sexual function and sexual relationships, in addition to her overall quality of life.

    This interview will focus on the diagnosis of dyspareunia and the therapies indicated for the management of this condition. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Renée Simone Yolanda Allen, MD, MHSc., FACOG
    OB/GYN Hospitalist, Mednax National Medical Group
    3M Physician Documentation Consultant
    ReachMD Radio Host

    Dr. Allen receives a salary from Mednax LLC and consulting fees from Ferring Pharmaceuticals and is a speaker for Quest Diagnostics.        

    David J. Portman, MD
    Director Emeritus, Columbus Center for Women’s Health Research
    Adjunct Instructor of Ob/Gyn
    Ohio State University
    Columbus, OH

    Dr. Portman receives consulting fees from AMAG Pharmaceuticals, Palatin, and Valeant Pharmaceuticals, is a speaker for AMAG Pharmaceuticals, Palatin and Valeant Pharmaceuticals and has contracted research with Endoceutics.


    • Sean T. Barrett has nothing to disclose.
    • Carole Drexel, PhD, CHCP has nothing to disclose.
    • Kia K. Gray, MPH has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Robert Schneider, MSW has nothing to disclose.
    • Mache Seibel, MD has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the benefits and risk profiles of the innovative therapeutic modalities indicated for the management of dyspareunia
  • Target Audience

    This activity is designed to meet the educational needs of Obstetricians/Gynecologists, Primary Care Physicians, Registered Nurses, Nurse Practitioners, and Physician Assistants.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Omnia Education has a core focus on women's health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.

  • Commercial Support

    This activity is supported by an independent educational grant from AMAG Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign-up for the Omnia Education newsletters.
Comprehensive women’s health CME.

Better education for a better you.

* Required

Join Omnia Education's community of women's health professionals.
Registration is free and easy.

Register Now